WARREN, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), is a clinical-stage specialty immunotherapy biotech company. As the biopharma ...

Researchers can now order their mutation of choice in bit.bio’s opti-ox TM powered human-iPSC derived cells, receiving consistent, defined, cryopreserved products that can be immediately incorporated ...

MINNEAPOLIS--(BUSINESS WIRE)--A recently published paper in Translational Lung Cancer Research details encouraging results from nonclinical studies conducted with Humanetics Corporation’s (Humanetics) ...

The PharmTech Group spoke with BIOVECTRA's director of Business Development, Nucleic Acid Modalities, Jessica Madigan, about the concept of flexibility in outsourcing and the 2024 BIO Convention.

Accurate cancer models are integral to the success of preclinical research yet have proven elusive. Mindy Goldsborough (ATCC, VA, USA) discusses the ongoing efforts to develop improved in vitro models ...